Skip to main content

Advertisement

Table 1 Clinical and biochemical characteristics of participants

From: Association between Brachial-Ankle pulse wave velocity and cardiac autonomic neuropathy in type 2 diabetes

Characteristic N = 148
cardiovascular autonomic neuropathy(%) 78(52.7)
Age(years) 59.8 ± 7.8
Male,n(%) 80(54.0)
Current smoker, n (%) 43(29.0)
Alcohol consumption, n (%) 37(25.0)
Hypertension, n (%) 81(54.7)
  Use of β-Blockers 34(22.9)
  Use of ACEI/ARB 67(45.3)
  Use of CCB 48(32.4)
Other antihypertensives 14(9.5)
Express as median(years) 6.0(2.0-11.0)
BMI(kg/m2) 24.4 ± 3.4
Waist-to-hip ratio 0.94(0.90-0.99)
systolic blood pressure(mmHg) 134.2 ± 18.1
diastolic blood pressure(mmHg) 78.3 ± 10.6
HbA1c(%) 8.0 ± 1.9
fasting glucose(mmol/l) 7.1(5.8-9.2)
Creatinine (μmol/L) 62.0(53.0-78.0)
eGFR( ml/min/1.73 m2) 107.0 ± 32.8
total cholesterol(mmol/l) 4.89 ± 1.52
Triglyceride(mmol/l) 1.61(1.05-2.34)
LDL cholesterol(mmol/l) 2.84(2.29-3.60)
HDL cholesterol(mmol/l) 1.09(0.93-1.33)
ACR(mg/g) 12.02(7.18-19.54)
baPWV(cm/sec) 1665.5(1482.0-1940.0)
Diabetic retinopathy, n (%) 25(16.9)
Diabetic peripheral neuropathy, n (%) 46(31.1)
  NSS score 5.0(2.0-6.0)
  NDS score 4.0(2.0-5.0)
Diabetic nephropathy, n (%) 33(22.2)
  1. BMI, body mass index; eGFR, modification of diet in renal disease study-glomerular filtration rate; ACR, albumin-to-creatinine ratio;ACEI/ARB, angiotensin converting enzyme inhibitors/Angiotensin II receptor blockers; CCB, Calcium channel blocker; NSS, neuropathy symptom score; NDS, neuropathy disability score.
  2. Data are means SD, median (25-75%), or number (percent).